PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

People with specific kind of lung cancer respond to new targeted treatment

2010-10-29
(Press-News.org) AURORA, Colo. (Oct. 28, 2010) - A study in the New England Journal of Medicine shows more than half of patients with a specific kind of lung cancer are responding positively to a treatment that targets the gene that drives their cancer.

The study shows 57 percent of patients with ALK-positive advanced non-small cell lung cancer responded partially or completely to a tablet called crizotinib, an investigational anaplastic lymphoma kinase (ALK) inhibitor. In some cases, the cancer becomes undetectable in body scans. The data is published in the October 28 issue of the New England Journal of Medicine.

"This study really supports the idea that we should always try to identify the patients that could benefit from a specific treatment in advance. By looking at lung cancer at the molecular level, we were able to find the patients most likely to respond to the ALK inhibitor and put them in this trial," said D. Ross Camidge, MD, PhD, one the of the study's authors, director of the lung cancer clinical program at University of Colorado Hospital (UCH) and the University of Colorado Cancer Center (UCCC).

"At the University of Colorado Hospital, we look after one of the largest groups of ALK positive lung cancer patients in the world. About one in 20 lung cancer patients are ALK positive. Most feel better within days of beginning the drug in the trial and many have returned to active lifestyles with their cancer under excellent control." said Camidge.

There were initially 82 ALK-positive lung cancer patients in the trial of the ALK inhibitor. ALK is believed to be a key driver of tumor development in some cancers.

Updated results from the study were presented earlier this month at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, reporting on a total of 113 patients and the impressive activity of the drug in these patients remained consistently high. The preliminary median progression-free survival (PFS), the time it takes for the cancer to first start to grow again, was 9.2 months.

"Initially the cancer melts away, but it's still there. And at some point, it usually figures out a way to get around this particular drug. We need to keep looking for new developments so that when this happens, we can supplement or replace the crizotinib with other treatments to help keep the cancer under long-term control," said Camidge.

At the very least, Camidge said it is crucial for anyone diagnosed with lung cancer to get their tumor tested. Several commercially available tests are available but the definitive test that qualifies for entry into the study is only conducted in those centers with the trial. The University of Colorado helped to develop these tests and many others for taking one disease - lung cancer - and revealing that it is, in fact, several different diseases at the molecular level. Each one of the diseases may need a different treatment.

Study Results Published in the New England Journal of Medicine

In the Part 2 expansion cohort study which included 82 patients with ALK-positive advanced NSCLC, 57 percent (n=47)(95% CI 46%, 68%) of patients treated with crizotinib (PF-02341066) at a dose of 250 mg twice daily, had either a complete or partial response to treatment. An additional 33 percent (n=27) met criteria for stable disease, including five unconfirmed partial responses. At eight weeks, the disease control rate (complete response (n=1) + partial response (n=46) + stable disease (n=24)) was 87 percent (n=71). Three patients with stable disease were not included in the disease control rate because their evaluation for response was outside a pre-specified timeframe.

At the time of the analysis, 77 percent of patients (n=63) continued to receive treatment with crizotinib (PF-02341066). The median duration of treatment was 6.4 months, and follow-up is ongoing. As such, the estimated probability of being progression-free at six months is 72 percent (95% CI: 61%, 83%).

Overall, crizotinib (PF-02341066) was generally well tolerated. The most commonly reported all-grade adverse events included nausea (n=44), diarrhea (n=39), vomiting (n=36), and mild visual disturbances (n=34). Grade 3 ALT (alanine aminotransferase) and AST (aspartate aminotransferase) elevations occurred in four patients. One patient experienced a Grade 4 ALT and one patient discontinued treatment due to Grade 3 ALT increases. Tumors in the analysis were primarily of adenocarcinoma histology, and patients tended to be young, and were never or former light smokers. Ninety-three percent of patients (n=76) had received at least one prior therapy and five patients were treated in the first-line setting.This Part 2 expansion cohort study of patients with ALK-positive advanced NSCLC, independent of the number of previous chemotherapies, followed the completion of the dose-escalation study which enrolled 37 advanced cancer patients with various tumors, including NSCLC, colorectal, pancreatic and inflammatory myofibroblastic tumor (IMT) tumors.

These data were previously presented at the 2010 American Society of Clinical Oncology Annual Meeting. INFORMATION:

About the University of Colorado Hospital

The University of Colorado Hospital is the Rocky Mountain region's leading academic medical center. It is ranked among the top 10 academic medical centers in the United States by the University HealthSystem Consortium and is ranked as one of the country's best hospitals by U.S. News & World Report. It is best known as an innovator in patient care and often as one of the first hospitals to bring new medicine to patients' bedsides. Based on the Anschutz Medical Campus in Aurora, Colo., the hospital's physicians are affiliated with the University of Colorado School of Medicine, part of the University of Colorado system.

About the University of Colorado Cancer Center

The University of Colorado Cancer Center is the Rocky Mountain region's only National Cancer Institute-designated comprehensive cancer center. NCI has given only 40 cancer centers this designation, deeming membership as "the best of the best." Headquartered on the University of Colorado Denver Anschutz Medical Campus, UCCC is a consortium of three state universities (Colorado State University, University of Colorado at Boulder and University of Colorado Denver) and five institutions (The Children's Hospital, Denver Health, Denver VA Medical Center, National Jewish Health and University of Colorado Hospital). Together, our 440+ members are working to ease the cancer burden through cancer care, research, education and prevention and control.



ELSE PRESS RELEASES FROM THIS DATE:

UNH's Fred Short adds seagrass data to major conservation study

2010-10-29
DURHAM, N.H. – A major new study that sounds a conservation alarm for the world's vertebrate species notes that the world's seagrass species are faring somewhat better, says a University of New Hampshire researcher who was a coauthor of the study. Fred Short, UNH research professor of natural resources and director of the worldwide program SeagrassNet, was among the 174 scientists who contributed to "The Impact of Conservation on the Status of the World's Vertebrates," released online this week in the journal Science. "Some areas, including New Hampshire, are experiencing ...

Potential new treatment for deadly nipah and hendra viruses identified by Weill Cornell researchers

2010-10-29
NEW YORK (Oct. 28, 2010) -- Scientists at Weill Cornell Medical College have identified a potential new treatment for the Nipah and Hendra viruses, two lethal and emerging viruses for which there is currently no treatment or vaccine available. The approach could also lead to new therapies for measles, mumps and the flu. The new research appears in today's edition of the prestigious journal Public Library of Science (PLoS) Pathogens. The Nipah and Hendra viruses are members of the genus Henipavirus, a new class of virus in the Paramyxoviridae family, which includes the ...

Spring into shape with the first Paddy Pallin Adventure Race of the season in the ACT! by AROC Sport

2010-10-29
Warm days are coming back in Canberra: time to head outside and make the most of what the Capital city has to offer, besides museums! For Canberrans, it's a great opportunity to come and enjoy their local playground with a twist: they are sure to discover some places through a different light, running, paddling and riding around with their team. For would-be participants who are not from the area, this is a chance to come down with colleagues, mates or family and make a weekend out of it. There are options for all, so bring the family and experience the great hands-on museums, ...

How To Find An Apartment In NYC

2010-10-29
Finding an apartment in New York is possible. Just do your homework. We spoke with Alicia Schwartz; she's the director of the rental resource http://www.HowToRentInNYC.com. The following is her advice. Think about hiring a broker. If your time is limited or you've been looking but haven't found the apartment of your dreams, a broker could make the difference. They may end up showing you an apartment you could have found yourself. But keep in mind they can show you places you would never have had access to. But if the thought of paying one really puts you off; usually ...

"An Eclectic Approach" Show Opening Night at Frary Gallery - Friday, Nov. 5th from 5-9 pm.

2010-10-29
Three artists, Gregg Stecker, Toby Thompson and Laura Eklund will show and discuss their work as well as the approach they take to conceive it - from graphic art to visionary. The show, "An Eclectic Approach," combines different styles of work - offering something for a variety of artistic tastes. "I wanted to put a show together that would cover a variety of preferences and tastes," say Gallery owner Lori Frary. "I believe we've achieved that with this group of artists. No matter what your preference, you won't be disappointed and you may discover something completely ...

Cherokee Uniforms Provide Nurses with Little Girls Dreams

2010-10-29
The adorable characters that make child's dreams come true in their very own virtual life, inspires Cherokee uniforms manufacturer to continue creating Disney inspired scrub tops. And this time, female professional health care workers are the targeted customers, not the children anymore. By combining femininity with the cutest and most adorable cartoon characters, Cherokee uniforms remain as the most sought after when it comes to such designs. Even if it comes to print scrubs, other than tooniforms, Cherokee proved to be among the most searched for scrub tops. http://www.youtube.com/watch?v=7pF1BlGtLvc The ...

Grand Opening VIVA MARKET Ogden, Utah

2010-10-29
¡VIVA! MARKET within its 15,000-sqft building allows you to enjoy a nostalgic experience with sights, sounds, smells, and products of Latin America in an upscale grocery market. This market represents the first of its kind in the Ogden area meeting the needs of Ogden's 45% Latin-American population. In addition to the grocery portion of the store, the market will include: a Panadería, Tortillaría, Taquería, Carnicería, Mexican Restaurant, and numerous other vendors. Come join us for the Grand Opening of ¡VIVA! MARKET on Saturday October 30th between 11 AM and 6 PM where ...

Dog Obedience Training - Apollo Inc Co-Founder/Dog Psychologist Says It's Time To Give Back

2010-10-29
It is time that there is an information network for people to be able to get everything they need to know in one spot, and not have to pay hundreds for a professional, or buy many different books to cover all the possible dog training and social behavior problems that affect dogs. A new blog dedicated to doing just that has been launched recently. Dan Bradie, an experienced dog psychologist, and co-founder of Apollo Inc says "People need the proper info and more importantly, the right info. You don't need a dog whisperer, YOU are the dog whisperer, you just don't know ...

Branch Water Tavern Presents: 'Twas the Night Before All Hallow's Eve A Halloween Party Worth Dressing Up For

2010-10-29
"We're talking 'Welcome to a nightmare on Shepherd Drive,' complete with booty-bumpin' beats by me - a.k.a. DJ Wine-O - the best bites and cocktails in town, and a costume contest with very cool prizes," says Evan Turner, Branch Water Tavern's front of the house guy and beverage extraordinaire. "In the interest of preserving what will be a shocking, mind-bending, whiskey addled experience, we'll spare you most of the gory details," says Turner. For now, just know this: • Best costume will be awarded a private chef tasting for four by Executive Chef David Grossman ...

Macro Sensors Demonstrates Calibration of EAZY-CAL LVDT Signal Conditioner on YouTube

2010-10-29
Macro Sensors provides instructions on how to connect, install and calibrate the EAZY-CAL MME-1000 mini-module, the world¡¦s most user-friendly LVDT signal conditioner, on http://www.youtube.com/user/MacroSensorsSales?feature=mhum.The YouTube video shows that a virtually effortless fingertip calibration routine can be used to field calibrate the EAZY-CAL signal conditioner in just mere seconds. The EAZY-CAL™ MME-1000 mini-module (http://www.macrosensors.com/MME-1000.html) saves time and money by eliminating repetitive null and span potentiometer adjustments ...

LAST 30 PRESS RELEASES:

To catch financial rats, a better mousetrap

Mapping the world's climate danger zones

Emory heart team implants new blood-pumping device for first time in U.S.

Congenital heart defects caused by problems with placenta

Schlechter named Cancer Moonshot Scholar

Two-way water transfers can ensure reliability, save money for urban and agricultural users during drought in Western U.S., new study shows

New issue of advances in dental research explores the role of women in dental, clinical, and translational research

Team unlocks new insights on pulsar signals

Great apes visually track subject-object relationships like humans do

Recovery of testing for heart disease risk factors post-COVID remains patchy

Final data and undiscovered images from NASA’s NEOWISE

Nucleoporin93: A silent protector in vascular health

Can we avert the looming food crisis of climate change?

Alcohol use and antiobesity medication treatment

Study reveals cause of common cancer immunotherapy side effect

New era in amphibian biology

Harbor service, VAST Data provide boost for NCSA systems

New prognostic model enhances survival prediction in liver failure

China focuses on improving air quality via the coordinated control of fine particles and ozone

Machine learning reveals behaviors linked with early Alzheimer’s, points to new treatments

Novel gene therapy trial for sickle cell disease launches

Engineering hypoallergenic cats

Microwave-induced pyrolysis: A promising solution for recycling electric cables

Cooling with light: Exploring optical cooling in semiconductor quantum dots

Breakthrough in clean energy: Scientists pioneer novel heat-to-electricity conversion

Study finds opposing effects of short-term and continuous noise on western bluebird parental care

Quantifying disease impact and overcoming practical treatment barriers for primary progressive aphasia

Sports betting and financial market data show how people misinterpret new information in predictable ways

Long COVID brain fog linked to lung function

Concussions slow brain activity of high school football players

[Press-News.org] People with specific kind of lung cancer respond to new targeted treatment